SCHEMBL25895682

SCHEMBL25895682

CCCCNc1nc(NCc2ccc(C(=O)NCCOCCOCCN)cc2)nc(N2CCN(c3ccc([N+](=O)[O-])cc3)CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 1/20 0.43
ALDH1A1 P00352 5/20 0.39
MAPT P10636 5/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTT P42858 1/20 0.39
EPHX2 P34913 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
HDAC1 Q13547 2/20 0.38
NPC1 O15118 1/20 0.38
TNF P01375 1/20 0.38
RAB9A P51151 1/20 0.38
PAX8 Q06710 1/20 0.38
NOD2 Q9HC29 1/20 0.38
NOD1 Q9Y239 1/20 0.38
APOBEC3A P31941 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
TP53 P04637 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13607363 0.88 CAMK2D (0.51) CAMK2DALDH1A1MAPTMEN1KMT2A
SCHEMBL23346105 0.76 GBA1 (0.46) MAPTLMNAEPHX2TP53HPGD
SCHEMBL23346110 0.74 CTNNB1 (0.45)
SCHEMBL13815210 0.73 ENO1 (0.58) EPHX2HDAC1
SCHEMBL18404775 0.71 ENO1 (0.56) CAMK2DALDH1A1MAPTMEN1KMT2A
SCHEMBL14930847 0.70 MAPT (0.57) CAMK2DALDH1A1MAPTMEN1KMT2A
SCHEMBL14930845 0.70 ENO1 (0.57) CAMK2DALDH1A1MAPTMEN1KMT2A
SCHEMBL18404729 0.69 ENO1 (0.55) CAMK2DALDH1A1MAPTMEN1KMT2A
SCHEMBL13616231 0.67 MAPT (0.37) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL14385565 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A CAMK2D 3446/4885ALDH1A1 3256/4885MAPT 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.